CAMP4 Therapeutics (NASDAQ:CAMP) CFO Kelly Gold Purchases 6,551 Shares

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) CFO Kelly Gold purchased 6,551 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were purchased at an average cost of $1.65 per share, with a total value of $10,809.15. Following the completion of the purchase, the chief financial officer directly owned 74,428 shares in the company, valued at approximately $122,806.20. This represents a 9.65% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

CAMP4 Therapeutics Price Performance

NASDAQ CAMP opened at $4.01 on Thursday. CAMP4 Therapeutics Corporation has a fifty-two week low of $1.32 and a fifty-two week high of $7.75. The stock’s 50-day moving average is $4.02 and its two-hundred day moving average is $4.31. The firm has a market cap of $208.24 million, a P/E ratio of -1.70 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its quarterly earnings data on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.11). CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. The company had revenue of $1.29 million during the quarter. On average, equities analysts expect that CAMP4 Therapeutics Corporation will post -0.84 EPS for the current year.

CAMP4 Therapeutics News Summary

Here are the key news stories impacting CAMP4 Therapeutics this week:

• Positive Sentiment: Insider buying signals management confidence. CEO Josh Mandel-Brehm, CFO Kelly Gold, Director Richard A. Young and insider Yuri Maricich collectively purchased 36,031 shares at $1.65 per share. The purchases increased their respective holdings, although the transactions were relatively small in dollar terms. Insider purchase filings
• Positive Sentiment: CAMP4 raised approximately $50.1 million in the second closing of its private placement. The proceeds are intended to fund CMP-002, the company’s lead antisense oligonucleotide candidate, and its early-stage pipeline. The financing included participation from institutional investors such as Janus Henderson, Balyasny Asset Management, Vivo Capital and 5AM Ventures. CAMP4 private placement announcement
• Positive Sentiment: CMP-002 moved closer to human testing. CAMP4 said it received Australian regulatory and ethics clearance to begin a Phase 1/2 trial for SYNGAP1-related disorder, a rare neurological disease with no approved disease-modifying therapies. Preclinical testing showed increased SYNGAP1 protein expression and improvements in disease-relevant animal models. CAMP4 financing and CMP-002 update
• Negative Sentiment: The financing is materially dilutive. CAMP4 issued more than 10.7 million common shares and approximately 21.9 million pre-funded warrants at roughly $1.53 per share-equivalent, potentially expanding the share count significantly. The discounted issuance may weigh on the stock even though it provides additional operating runway.
• Neutral Sentiment: Clinical execution remains the key catalyst and risk. The Phase 1/2 trial could provide important validation, but CMP-002 remains investigational and preclinical results do not guarantee safety or efficacy in humans.

Institutional Trading of CAMP4 Therapeutics

A number of large investors have recently bought and sold shares of CAMP. Janus Henderson Group PLC increased its position in CAMP4 Therapeutics by 35.9% in the 4th quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock valued at $38,807,000 after acquiring an additional 1,666,666 shares in the last quarter. Vivo Capital LLC boosted its stake in CAMP4 Therapeutics by 8.3% during the 4th quarter. Vivo Capital LLC now owns 4,246,568 shares of the Wireless communications provider’s stock worth $26,031,000 after acquiring an additional 325,000 shares during the last quarter. Balyasny Asset Management L.P. bought a new stake in CAMP4 Therapeutics in the fourth quarter valued at approximately $14,938,000. Adage Capital Partners GP L.L.C. increased its position in shares of CAMP4 Therapeutics by 11.3% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,181,679 shares of the Wireless communications provider’s stock valued at $13,374,000 after buying an additional 220,895 shares in the last quarter. Finally, SummitTX Capital L.P. bought a new position in shares of CAMP4 Therapeutics during the 1st quarter valued at about $1,497,000.

Analysts Set New Price Targets

Several equities analysts recently weighed in on CAMP shares. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Chardan Capital set a $6.50 price objective on CAMP4 Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 10th. Rodman & Renshaw initiated coverage on shares of CAMP4 Therapeutics in a research note on Tuesday, April 14th. They issued a “buy” rating and a $7.00 price objective on the stock. Weiss Ratings lowered shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 21st. Finally, Zacks Research cut shares of CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 15th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, CAMP4 Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $8.36.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.